Page 167 - 2021_12-Haematologica-web

CCR1 drives dissemination of multiple myeloma plasma cells
dosing identifies hyperexpression of pro- teasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118(13):3512- 3524.
29. Hewett DR, Vandyke K, Lawrence DM, et al. DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia. 2017;19(12):972-981.
30. Asosingh K, Günthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 medi- ates binding to bone marrow endothelium. Cancer Res. 2001;61(7):2862.
31. Mrozik KM, Cheong CM, Hewett D, et al. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. Br J Haematol. 2015;171(3):387-399.
32. Groen RWJ, de Rooij MFM, Kocemba KA, et al. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica. 2011;96 (11):1653.
33. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 regulates extra-medullary myelo- ma through epithelial-mesenchymal-transi- tion-like transcriptional activation. Cell Rep. 2015;12(4):622-635.
34. Yang Y, Macleod V, Bendre M, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 2005;105(3):1303-1309.
35. Cheong CM, Mrozik KM, Hewett DR, et al. Twist-1 is upregulated by NSD2 and
contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-posi- tive multiple myeloma. Cancer Lett. 2020; 475:99-108.
36. Zhu Y, Gao X-M, Yang J, et al. C-C chemokine receptor type 1 mediates osteo- pontin-promoted metastasis in hepatocel- lular carcinoma. Cancer Sci. 2018;109(3): 710-723.
37. Lord BI, Woolford LB, Wood LM, et al. Mobilization of early hematopoietic pro- genitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 . Blood. 1995;85 (12):3412-3415.
38. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and func- tion of chemokine receptors in human mul- tiple myeloma. Leukemia. 2003;17(1):203- 210.
39. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96(2):671-675.
40. Wang X-T, He Y-C, Zhou S-Y, et al. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relation- ship with bone disease and clinical charac- teristics. Leuk Res. 2014;38(5):525-531.
41. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth fac- tor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 1999;93(1):235-241.
42.Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necro- sis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res. 2004;10(6):1901-1910. Gilliland CT, Salanga CL, Kawamura T, Trejo J, Handel TM. The chemokine recep- tor CCR1 is constitutively active, which leads to G protein-independent, -arrestin- mediated internalization. J Biol Chem. 2013;288(45):32194-32210.
43.
44.
45.
46.
Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J. 2014;4(12):e262.
Diamond P, Labrinidis A, Martin SK, et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma associated bone loss. J Bone Miner Res. 2009;24(7):1150-1161.
Conroy MJ, Galvin KC, Kavanagh ME, et al. CCR1 antagonism attenuates T cell traf- ficking to omentum and liver in obesity- associated cancer. Immunol Cell Biol. 2016;94(6):531-537.
47.Tak PP, Balanescu A, Tseluyko V, et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013;72(3):337-344.
48. Zhan F, Huang Y, Colla S, et al. The molec- ular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
haematologica | 2021; 106(12)
3187